Dr. Fred Sancilio reports

LOBE SCIENCES LTD. ANNOUNCES DEBT SETTLEMENT

Lobe Sciences Ltd. has settled an outstanding debt of $11,596.22 owed to Gibbson Law PC for legal services previously provided to the company.

In satisfaction of this obligation, Lobe has issued 546,206 common shares of the company to Gibbson at a deemed price of 2.123 cents per share. The shares were issued on May 13, 2025, and are subject to applicable regulatory hold periods under Canadian securities laws.

About Lobe Sciences Ltd.

Lobe Sciences is a biopharmaceutical company focused on developing innovative therapies for rare and underserved conditions. Through its wholly owned subsidiary, Altemia Inc., and its majority-owned subsidiary, Cynaptec Pharmaceuticals Inc., Lobe is advancing a patented lipid-based platform for treating sickle cell disease and a novel oral analogue of psilocin-conjugated psilocin -- targeted at chronic cluster headache and other neurological disorders. These programs address significant unmet medical needs with the potential to improve outcomes in both hematologic and neuropsychiatric patient populations.

We seek Safe Harbor.